Passiflora Caerulea L.: A Systematic Review of Its Phytochemical Diversity, Ethnopharmacological Applications, And Modern Therapeutic

Sanjay Kumar[1], Dr. Prof. Mihir Y Parmar[2]
[1,2]*Department of Pharmacology, Krishna School of Pharmacy, Drs. Kiran and Pallavi Patel Global University, Krishna Edu Campus, Varnama, Vadodara, Gujarat, India*

***Abstract*—*Passiflora caerulea* L. is an important member of the Passifloraceae family, traditionally utilized across South America, Europe, and parts of Asia for the management of insomnia, anxiety, inflammation, and various nervous system disorders. Over the past two decades, increasing phytochemical and pharmacological investigations have highlighted the medicinal relevance of this species, particularly due to its diverse spectrum of bioactive metabolites. Recent analytical studies employing LC-MS, HPLC, and chromatographic profiling have identified flavonoids (vitexin, isovitexin, orientin, chrysin), alkaloids (harman, harmine), phenolic acids (chlorogenic and caffeic acid), and cyanogenic glycosides as the major chemical constituents responsible for its biological activities.**

A growing body of preclinical evidence demonstrates significant antioxidant, anti-inflammatory, analgesic, anxiolytic, sedative, and antimicrobial properties associated with various parts of *P. caerulea*. These activities are largely attributed to its ability to modulate oxidative stress, suppress pro-inflammatory cytokines, and interact with neurotransmitter systems, particularly the GABAergic pathway. Despite promising pharmacological findings, current literature reveals limited standardization of extracts, inadequate dose-response studies, and a scarcity of well-designed toxicological assessments.

This review consolidates existing scientific data on the phytochemistry, pharmacological effects, and safety profile of *P. caerulea*, while identifying critical research gaps that must be addressed to support its future development as a standardized herbal therapeutic or nutraceutical candidate. The summarized evidence further underscores the relevance of this plant for the exploration of anti-arthritic potential, particularly in models involving oxidative stress and cytokine imbalance.

***Index Terms*—*Passiflora caerulea*, flavonoids, phytochemistry, pharmacology, antioxidant activity, anti-inflammatory activity, herbal therapeutic.**

I. INTRODUCTION

The genus *Passiflora* comprises more than 550 species within the family Passifloraceae, representing one of the most morphologically and pharmacologically diverse groups of medicinal plants in the tropics and subtropics [1]. Among these, *Passiflora caerulea* L., commonly known as the Blue Passionflower, has emerged as an important ethnomedicinal species due to its wide range of traditional uses and distinctive phytochemical composition. Although several *Passiflora* species—particularly *P. incarnata*—have been well documented in pharmacopoeias and herbal compendia, *P. caerulea* has gained scientific attention in recent years owing to its notable neuropharmacological, antioxidant, anti-inflammatory, and antimicrobial properties [2–4].

Traditional medicinal practices in South America have long employed *P. caerulea* for conditions associated with anxiety, insomnia, nervous agitation, palpitations, and gastrointestinal disturbances, reflecting its significant role in indigenous and folk pharmacotherapy [3]. European phytotherapeutic traditions similarly recognize the plant for its calming and sedative properties. Scientific validation of these uses is increasingly supported by modern phytochemical investigations identifying flavonoids (vitexin, isovitexin, chrysin), β-carboline alkaloids (harman, harmine), phenolic acids, and glycosides as major bioactive constituents [5–7]. These compounds contribute to a broad pharmacological spectrum that includes GABAergic modulation, antioxidant defense,

anti-inflammatory effects, and neuroprotective actions.

Advances in chromatographic and spectrometric techniques such as LC-MS/MS and HPLC fingerprinting have allowed deeper characterization of *P. caerulea*, revealing significant chemotaxonomic variation across geographic regions, environmental conditions, and plant parts [8,9]. These findings underscore the importance of comprehensive quality-control and standardization strategies, particularly because misidentification with other Passiflora species is common in commercial markets and can affect therapeutic consistency [13–15].

Pharmacological studies provide compelling evidence that *P. caerulea* possesses anxiolytic, sedative, anti-inflammatory, antioxidant, and antimicrobial activities, many of which parallel or complement the effects of *P. incarnata* [10–12,24]. The presence of chrysin—a potent modulator of the GABAA_AA receptor benzodiazepine site—further highlights its therapeutic relevance and potential for development as a natural anxiolytic agent [7]. In addition, phenolic acids and flavonoid derivatives contribute to its antioxidant and anti-inflammatory potential, making it a candidate for managing oxidative stress–related disorders [10,22,23].

Despite promising pharmacological evidence, several scientific gaps and challenges remain. Current research on *P. caerulea* is predominantly preclinical, with limited mechanistic insights and an absence of well-designed clinical trials. Toxicological data are incomplete, particularly regarding long-term safety, reproductive toxicity, and the role of cyanogenic glycosides such as gynocardin [18,20,32]. Furthermore, environmental and genetic factors affecting phytochemical composition complicate standardization efforts and highlight the need for robust pharmacognostic markers [14–17].

Given these considerations, a comprehensive and updated review of *P. caerulea* is essential to consolidate existing knowledge, identify research gaps, and provide a scientific foundation for further investigation. This review aims to critically synthesize the botanical characteristics, ethnomedicinal significance, phytochemical composition, pharmacological properties, toxicological profile, and future research prospects of *Passiflora caerulea*, with the objective of supporting its advancement as a validated phytomedicinal resource.



Figure 1. Overview of major pharmacological activities of Passiflora caerulea.

II. BOTANICAL CHARACTERIZATION AND DISTRIBUTION

2.1. Taxonomy and Nomenclature

Passiflora caerulea L. is a validated and well-recognized species within the family Passifloraceae, one of the most taxonomically diverse families of climbing and ornamental plants found across tropical and subtropical ecosystems [1]. The genus *Passiflora* comprises more than 550 species distributed into several subgenera, with *P. caerulea* placed under the subgenus *Passiflora*, supersection *Stipulata*, section *Passiflora* [1,8]. The species is commonly known by its vernacular name "Blue Passionflower," which refers to the distinctive blue-to-purple corona filaments of its flowers.

Despite morphological similarities among commercially traded Passiflora species—particularly *P. incarnata* and *P. edulis*—*P. caerulea* possesses stable taxonomic markers that permit reliable identification [14,15]. Its characteristic palmate leaves, multilayered corona filaments, and orange ovoid fruits allow clear differentiation, making taxonomy critical for ensuring botanical purity in herbal preparations and nutraceutical applications.

2.2. Morphological Description

2.2.1.Habit and Stem

P. caerulea is a perennial, woody-based climbing vine that relies on axillary tendrils for support. It grows vigorously, with stems extending up to 10–15 meters in favorable subtropical climates [2,14]. The stems are glabrous, green, and longitudinally striated, reflecting

typical structural features of climbing Passifloraceae members.

2.2.2.Leaves

Leaves are alternate, simple, and palmately 5-lobed—occasionally ranging from 3 to 7 lobes depending on environmental conditions. Each lobe is lanceolate to oblong-lanceolate, with smooth margins and a glossy surface texture [3]. A distinguishing morphological feature is the presence of 2–4 nectary glands on the upper petiole surface, which serves as a taxonomically reliable marker for species identification [9,14].

2.2.3.Flowers

The flowers of *P. caerulea* are among the most distinctive within the genus and represent a key ornamental trait. Flowers are solitary, axillary, and large (8–10 cm in diameter) with a symmetrical radial arrangement [3,10]. They possess:

- Five sepals (white to pale pink)
- Five petals of similar coloration
- A multilayered corona composed of blue, violet, white, and dark purple filaments arranged concentrically
- A central androgynophore, elevated and supporting the reproductive organs
- Five stamens, each with a versatile anther
- Three stigmas, positioned atop a trilocular ovary

The floral morphology is highly specialized, aiding in both pollinator attraction and taxonomic verification [2].

2.2.4.Fruits and Seeds

The fruit is an ovoid berry, 5–7 cm long, turning bright orange or yellow at full maturity. Although edible, the fruit is generally not consumed widely due to mild flavor. It contains numerous dark-colored seeds embedded in a red to orange gelatinous aril [11]. The fruit structure contributes to seed dispersal and botanical identification.



Figure 2. Morphological characteristics of Passiflora caerulea showing leaves, flowers, and fruits.

2.3. Microscopic Characteristics (Pharmacognostic Features)

Accurate microscopic examination is essential for detecting adulteration, especially in powdered raw materials. Key diagnostic features include:

- Epidermal cells with slightly undulating anticlinal walls
- Unicellular covering trichomes sparsely present
- Paracytic stomata on the lower epidermis
- Collateral vascular bundles within leaf veins
- Calcium oxalate crystals, predominantly prismatic type
- Secretory cells associated with flavonoid storage

These microscopic markers play a critical role in pharmacognostic authentication and quality-control testing, as recommended by WHO and the Indian Pharmacopoeia [16,17].

2.4. Geographical Distribution and Ecology

P. caerulea is native to subtropical regions of South America—specifically Argentina, Brazil, Paraguay,

Uruguay, and Chile [3]. Due to its high ecological adaptability and ornamental attractiveness, the species has now naturalized across various continents including:

- Southern Europe (Mediterranean region)
- South Africa
- Australia
- Southeastern United States
- East Asia (China, Japan)

Its capacity to survive frost and tolerate temperatures as low as –10°C distinguishes it from other Passiflora species, many of which are sensitive to cold [13]. This resilience is attributed to its seasonal dormancy mechanism, wherein the aerial parts die back in winter while root systems remain viable.

The species prefers:

- Well-drained sandy-loamy soils
- Moderate humidity
- Full to partial sunlight
- Neutral to slightly acidic pH

Ecological adaptability contributes to widespread cultivation, increasing global availability for medicinal research [34].

2.5. Habitat Preferences

In its natural habitat, *P. caerulea* grows in:

- Forest edges
- Riverbanks
- Open fields
- Disturbed lands
- Semi-shaded understory regions

Its invasive potential has been noted in some regions, requiring controlled cultivation practices.

III. ETHNOMEDICINAL AND TRADITIONAL USES

3.1. Historical Background

Passiflora caerulea L. has played an integral role in traditional healing systems of South America for centuries. Indigenous communities in Paraguay, Argentina, Brazil, and Uruguay used the leaves, flowers, and aerial parts of the plant to manage anxiety, insomnia, emotional disturbances, and inflammatory conditions [3]. The calming effects of *P. caerulea* were recognized early in native ethnobotanical knowledge, where infusions prepared from fresh or dried leaves were consumed to reduce nervous agitation and promote sleep.

During the colonial period, Spanish and Portuguese explorers documented the plant's medicinal value and introduced it into European herbal pharmacotherapy, where it became known for its sedative and spasmolytic actions [3,21]. By the late 19th and early 20th centuries, *Passiflora* preparations were included in several European pharmacopeias as natural remedies for neurasthenia, hysteria, and mild sleep disorders. Although *P. incarnata* became more widely commercialized, *P. caerulea* continued to be used in herbal medicine across Europe and South America.

3.2. Traditional Uses in South American Medicine

Ethnopharmacological surveys confirm that *P. caerulea* has been used extensively by South American communities as a multipurpose medicinal plant [3,19]:

Major Ethnomedicinal Applications:

- Relief from anxiety, nervous tension, and restlessness
- Treatment of insomnia and disturbed sleep
- Management of inflammatory conditions, including joint pain
- Relief of muscle spasms and gastrointestinal cramps
- Reduction of palpitations and mild forms of cardiovascular stress
- Use as a mild analgesic for headaches and body pain
- Treatment of skin infections using poultices from crushed leaves

Infusions and decoctions were the most common traditional preparations, while poultices and compresses were applied externally for inflammation or wounds.

3.3. European and Global Herbal Use

After its introduction into Europe, *P. caerulea* was incorporated into various herbal formulations used for nervous system disorders. European practitioners widely employed the plant for:

- Mild to moderate anxiety
- Sleep disorders
- Neurasthenia
- Menopausal symptoms
- Nervous palpitations
- Psychosomatic stress-related disorders [21]

In Germany and Italy, the plant appeared in traditional pharmacopeias as a calming sedative and was often combined with valerian, lemon balm, and hops in herbal sleep formulations.
Today, global herbal medicine markets recognize *P. caerulea* as an ingredient in dietary supplements, calming teas, tinctures, and standardized extracts marketed for stress relief and sleep support.

3.4. Comparison with Other Passiflora Species
While *P. incarnata* remains the best-studied species of the genus, *P. caerulea* is often used interchangeably due to similarities in flavonoid composition. However, distinct chemical These variations highlight the importance of species-specific research.

Feature	*P. caerulea*	*P. incarnata*	References
Main Flavonoids	Vitexin, isovitexin, chrysin	Vitexin, isovitexin, Orientin	[5,6,7]
Akaloid	Low-moderate beta carbolines	Higher β-carboline content	[7,8]
Traditional uses	Anxiety, insomnia, inflammation	Anxiety, insomnia	[3,21]
Global commerical uses	Moderate	Very high	[29]

3.5. Medicinal Plant Preparations Traditionally Used
Traditional preparations of *P. caerulea* vary by culture and therapeutic purpose:

1. Herbal Infusion (Tea)
- Leaves or flowers steeped in hot water
- Used for calming, anxiolytic, and sleep-promoting effects

2. Decoction
- Boiled aerial parts
- Used for palpitations, headaches, and menstrual pain

3. Tincture
- Ethanol-based extract
- Used in European herbal medicine for nervous disorders

4. Poultice
- Fresh leaf paste applied to skin
- Used for inflammation, swelling, and wounds

5. Smoking/Dried Herb Use
Reported in indigenous South American practices to reduce stress and induce relaxation.
These traditional uses guided modern pharmacological evaluations.

3.6. Ethnomedical Relevance to Modern Pharmacology

Ethnomedicinal applications directly correlate with experimentally validated activities:

Traditional Use	Modern Pharmacological Evidence	References
Anxiety & stress	GABA modulation, sedative effects	[7,11,21]
Insomnia	Sleep-enhancing CNS actions	[21]
Pain & inflammation	Anti-inflammatory	[12,25]
Digestive disorders	Antispasmodic effects	[3]
Skin conditions	Antimicrobial & antioxidant	[24]

This alignment between traditional knowledge and modern pharmacology supports the plant's therapeutic relevance.

IV. PHYTOCHEMISTRY OF *PASSIFLORA CAERULEA*

4.1. Overview of Phytochemical Composition
The therapeutic potential of *Passiflora caerulea* L. is largely attributed to its complex and diverse phytochemical profile. Extensive phytochemical investigations have demonstrated that the plant contains a wide range of secondary metabolites, including flavonoids, alkaloids, phenolic acids, glycosides, and minor volatile constituents [4,8]. These compounds are unevenly distributed across different plant parts—leaves, flowers, stems, and fruits—and their concentration is influenced by geographical origin, environmental factors, and extraction methods [9,34].

Among the various phytochemical classes, flavonoids are considered the principal bioactive constituents responsible for most of the pharmacological effects associated with *P. caerulea*. Advanced analytical techniques such as high-performance liquid chromatography (HPLC), liquid chromatography–mass spectrometry (LC-MS/MS), and metabolomic profiling have significantly improved the characterization and quantification of these compounds [5,9,30].

4.2. Flavonoids: Major Bioactive Constituents

Flavonoids constitute the most abundant and pharmacologically relevant class of compounds in *P. caerulea*. The species is particularly rich in C-glycosyl flavones, which exhibit enhanced metabolic stability compared to O-glycosyl flavonoids [5,6].

Major Flavonoids Identified

The most commonly reported flavonoids include:

- Vitexin
- Isovitexin
- Orientin
- Lucenin II
- Chrysin

Vitexin and isovitexin are considered chemical markers for the quality control and standardization of *Passiflora* extracts [5]. These compounds have demonstrated anxiolytic, antioxidant, and anti-inflammatory properties in experimental studies. Chrysin (5,7-dihydroxyflavone), although present in lower concentrations, is of particular pharmacological interest due to its affinity for the benzodiazepine-binding site of the GABAA_AA receptor, contributing to sedative and anxiolytic effects [7].

Flavonoid biosynthesis in *P. caerulea* is influenced by environmental stress, light exposure, and soil composition, resulting in quantitative variation across different cultivation regions [34]. Such variability reinforces the need for standardized cultivation and extraction protocols.

4.3. Alkaloids

In addition to flavonoids, *P. caerulea* contains β-carboline alkaloids, albeit at lower concentrations than those found in *P. incarnata*. Identified alkaloids include:

- Harman
- Harmine
- Harmol

These alkaloids are pharmacologically significant due to their monoamine oxidase (MAO) inhibitory activity, which may contribute to antidepressant and CNS-modulating effects [9,10]. However, their low abundance in *P. caerulea* suggests a supportive rather than dominant role in its overall pharmacological profile.

4.4. Phenolic Acids and Other Polyphenols

Phenolic acids represent another important class of compounds in *P. caerulea*. Commonly identified phenolic acids include:

- Chlorogenic acid
- Caffeic acid
- p-Coumaric acid

These compounds exhibit potent antioxidant activity by scavenging free radicals and inhibiting lipid peroxidation, thereby contributing to the plant's protective effects against oxidative stress and inflammation [10,22,23]. Synergistic interactions between flavonoids and phenolic acids are believed to enhance the overall antioxidant capacity of *P. caerulea* extracts.

4.5. Cyanogenic Glycosides

Cyanogenic glycosides, particularly gynocardin, have been reported in the leaves of *P. caerulea* [18]. These compounds play a defensive role in the plant but can release hydrogen cyanide upon enzymatic hydrolysis. Although the levels detected in medicinal preparations are generally low, improper processing or excessive consumption may pose safety concerns.

The presence of cyanogenic glycosides underscores the importance of controlled extraction methods, appropriate drying techniques, and dose regulation when developing medicinal formulations from *P. caerulea* [18,27].

4.6. Minor Constituents and Volatile Compounds

Minor phytoconstituents such as sterols, triterpenoids, and trace volatile compounds have also been detected in *P. caerulea* extracts [19]. Although these components are present in small quantities, they may contribute to synergistic pharmacological effects and enhance bioavailability of major constituents.

4.7. Analytical Techniques for Phytochemical Identification

Modern phytochemical investigations of *P. caerulea* rely on advanced analytical techniques, including:

- HPLC and HPTLC for flavonoid fingerprinting and standardization [5,15]
- LC-MS/MS for metabolomic profiling and compound identification [9,30]
- UV–Visible spectrophotometry for preliminary phenolic estimation [19]

These techniques are essential for ensuring reproducibility, quality assurance, and regulatory compliance of herbal products.

4.8. Table and Figure Placement

Table 2. Major Phytochemical Constituents of *Passiflora caerulea*

Compound Class	Compounds	Biological Activity	References
Flavonoids	Vitexin, Isovitexin	Anxiolytic, Antioxidant	[5,6,7]
Flavonoids	Chrysin	CNS modulation	[7]
Alkaloids	Harman, Harmine	MAO inhibition	[9,10]
Phenolic acid	Chlorogenic acid	Anti-inflammatory	[10,22]
Glycosides	Gynocardin	Defensive/Toxicological relevance	[18]

4.9. Significance of Phytochemistry in Drug Development

The diverse phytochemical composition of *P. caerulea* provides a strong scientific basis for its traditional medicinal use and modern pharmacological exploration. The presence of stable C-glycosyl flavonoids, coupled with supportive alkaloids and phenolic acids, positions *P. caerulea* as a promising source of bioactive compounds for the development of herbal medicines, nutraceuticals, and functional foods [31,33]. However, further studies focusing on bioavailability, metabolism, and synergistic interactions are required to translate phytochemical potential into clinical applications.

V. PHARMACOLOGICAL ACTIVITIES OF *PASSIFLORA CAERULEA*

5.1. Overview

The pharmacological potential of *Passiflora caerulea* L. is supported by extensive preclinical investigations that validate many of its traditional uses. Experimental studies have demonstrated that extracts and isolated phytoconstituents of *P. caerulea* exert significant effects on the central nervous system, inflammatory pathways, oxidative stress mechanisms, microbial growth, and neuronal protection. These biological activities are primarily attributed to the synergistic interaction of flavonoids, alkaloids, and phenolic compounds present in the plant [4,10,12].

5.2. Anxiolytic and Sedative Activity

The most extensively studied pharmacological effect of *P. caerulea* is its anxiolytic and sedative activity. Experimental animal models have shown that hydroalcoholic and ethanolic extracts of *P. caerulea* significantly reduce locomotor activity, prolong sleep duration, and alleviate anxiety-like behavior [1,11,21]. Flavonoids such as chrysin, vitexin, and isovitexin are considered the primary mediators of these effects. Chrysin, in particular, has demonstrated high affinity for the benzodiazepine-binding site of the GABAA_AA receptor, resulting in CNS depressant and anxiolytic effects without producing marked muscle relaxation or dependence [7]. This mechanism distinguishes *P. caerulea* from synthetic benzodiazepines and supports its use as a safer alternative for managing anxiety and sleep disorders.

5.3. Anti-inflammatory Activity

Several studies have reported significant anti-inflammatory activity of *P. caerulea* extracts in experimental models. The anti-inflammatory effect is mediated through inhibition of pro-inflammatory mediators such as prostaglandins, cytokines, and nitric oxide [12,25]. Flavonoids and phenolic acids suppress key signaling pathways including NF-κB and COX-2, thereby reducing inflammatory responses.

In vivo models have demonstrated that *P. caerulea* extracts reduce edema formation and inflammatory cell infiltration, supporting its traditional use in treating inflammatory conditions such as joint pain and muscular discomfort [22,25]. The antioxidant activity of the plant further complements its anti-

inflammatory effects by attenuating oxidative stress–induced tissue damage.

5.4. Antioxidant Activity

Oxidative stress plays a central role in the pathogenesis of numerous chronic diseases, including neurodegenerative and inflammatory disorders. *P. caerulea* exhibits strong antioxidant activity, as demonstrated by in vitro assays such as DPPH, ABTS, and lipid peroxidation inhibition tests [10,23].

The antioxidant effects are primarily attributed to flavonoids and phenolic acids, which neutralize free radicals, chelate metal ions, and enhance endogenous antioxidant defenses [22,26]. Synergistic interactions among these compounds enhance the overall antioxidant potential of the plant extract, contributing to its protective effects against oxidative damage.

5.5. Neuroprotective Activity

Emerging evidence suggests that *P. caerulea* possesses neuroprotective properties, particularly in models of oxidative stress and neurotoxicity. Flavonoid-rich extracts have been shown to protect neuronal cells from oxidative damage, reduce neuroinflammation, and modulate neurotransmitter balance [23,24].

The neuroprotective activity of *P. caerulea* is closely linked to its antioxidant capacity and GABAergic modulation, which collectively stabilize neuronal function and prevent excitotoxicity. These findings indicate potential applications in managing neurodegenerative disorders and cognitive dysfunction.

5.6. Antimicrobial Activity

The antimicrobial potential of *P. caerulea* has been demonstrated against a range of bacterial and fungal pathogens. Extracts prepared from leaves and aerial parts exhibit inhibitory activity against both Gram-positive and Gram-negative bacteria, as well as certain fungal strains [24].

Phenolic compounds and flavonoids disrupt microbial cell membranes and interfere with enzyme systems essential for microbial survival. These findings support the traditional use of *P. caerulea* in treating skin infections and wounds.

5.7. Antispasmodic and Gastrointestinal Effects

Traditional use of *P. caerulea* for gastrointestinal disturbances is supported by experimental evidence demonstrating antispasmodic activity. The plant relaxes smooth muscle tissues, thereby reducing spasms and abdominal discomfort [3,21]. This effect is believed to involve calcium channel modulation and central nervous system relaxation mechanisms.



Figure 3. Mechanisms of Pharmacological Action of *Passiflora caerulea*

5.8. Significance in Drug Discovery

The broad pharmacological spectrum of *P. caerulea* highlights its potential as a multi-target therapeutic agent. The synergistic interaction of flavonoids, alkaloids, and phenolic acids positions the plant as a valuable candidate for further pharmaceutical and nutraceutical development [31,33]. However, translation from preclinical findings to clinical applications requires rigorous standardization, dose optimization, and safety evaluation.

VI. TOXICOLOGICAL PROFILE AND SAFETY CONSIDERATIONS

6.1. General Safety Overview

The toxicological evaluation of *Passiflora caerulea* L. is an essential component in determining its suitability for medicinal and nutraceutical applications. Although the plant has been used traditionally for centuries, scientific safety assessments are comparatively limited and largely confined to preclinical investigations. Available toxicological studies suggest that *P. caerulea* exhibits a favorable safety profile when administered at therapeutic doses, particularly in short-term and sub-chronic exposure models [27,28].

Acute toxicity studies conducted using rodent models have reported high median lethal dose (LD_{50}) values, indicating low acute toxicity. These findings support the historical perception of *P. caerulea* as a relatively

safe medicinal plant when appropriately prepared and dosed [27].

6.2. Acute Toxicity Studies

Acute oral toxicity assessments of *P. caerulea* extracts have generally been performed according to OECD guidelines. In such studies, no mortality or significant behavioral abnormalities were observed in experimental animals at doses up to 2000 mg/kg body weight [27]. Observed parameters—including locomotor activity, food and water intake, posture, and grooming behavior—remained within normal limits.

These findings indicate that *P. caerulea* extracts fall within the category of substances with low acute toxicity and provide a scientific basis for selecting safe dose ranges in pharmacological experiments.

6.3. Sub-Chronic Toxicity and Organ Safety

Sub-chronic toxicity studies evaluating repeated administration of flavonoid-rich extracts of *P. caerulea* over periods of 28 to 90 days have demonstrated minimal adverse effects on major organ systems [28]. Hematological parameters such as hemoglobin concentration, red and white blood cell counts, and platelet levels were not significantly altered. Similarly, biochemical markers of liver and kidney function—including serum transaminases, creatinine, and urea—remained within physiological ranges.

Histopathological examination of vital organs (liver, kidney, heart, and spleen) revealed no evidence of cellular degeneration, necrosis, or inflammatory infiltration at therapeutic dose levels, further supporting the safety of *P. caerulea* for short-term use [28].

6.4. Cyanogenic Glycosides: A Safety Concern

One notable safety consideration associated with *P. caerulea* is the presence of cyanogenic glycosides, particularly gynocardin, primarily localized in the leaves [18]. Cyanogenic glycosides can release hydrogen cyanide upon enzymatic hydrolysis, posing potential toxicity risks if consumed in large quantities or improperly processed.

However, studies indicate that the concentration of these compounds in medicinal preparations is generally low and does not pose significant risk when proper drying, extraction, and dosage control are applied [18,27]. Nevertheless, their presence necessitates caution during formulation development and reinforces the importance of standardized extraction protocols.

6.5. Reproductive and Developmental Toxicity

Limited data are available regarding the reproductive and developmental toxicity of *P. caerulea*. Available evidence from studies on Passiflora species suggests the absence of teratogenic effects at therapeutic doses; however, comprehensive reproductive toxicity studies specific to *P. caerulea* remain insufficient [20]. Until further evidence is available, the use of *P. caerulea* during pregnancy and lactation should be approached with caution.

6.6. Neurotoxicity and CNS Safety

Given the CNS-active nature of *P. caerulea*, evaluation of neurotoxicity is particularly important. Experimental studies have not reported neurotoxic effects such as convulsions, severe sedation, or motor impairment at therapeutic dose levels [11,21]. The mild sedative action observed is considered pharmacological rather than toxic, distinguishing *P. caerulea* from synthetic sedatives that often produce tolerance and dependence.

However, the presence of β-carboline alkaloids with MAO-inhibitory activity suggests potential interactions with antidepressant medications and warrants further investigation [9,10].

6.7. Drug–Herb Interaction Potential

The potential for herb–drug interactions represent an emerging area of concern. Flavonoids and alkaloids present in *P. caerulea* may influence cytochrome P450 enzymes and monoamine oxidase pathways, thereby altering the metabolism of co-administered drugs [10,35]. Although clinical evidence is limited, caution is advised when *P. caerulea* is used alongside CNS depressants, antidepressants, or sedative medications.

6.8. Regulatory and Safety Recommendations

International organizations such as the World Health Organization emphasize the necessity of comprehensive toxicological evaluation, quality control, and post-marketing surveillance for herbal medicines [16]. For *P. caerulea*, future safety assessments should include:

- Chronic toxicity studies
- Genotoxicity and mutagenicity evaluations

- Reproductive toxicity studies
- Clinical safety trials

Adherence to WHO and Indian Pharmacopoeia guidelines will be essential for regulatory acceptance and safe commercialization [16,17].

VII. PHARMACOGNOSTIC AND QUALITY-CONTROL PARAMETERS

7.1. Importance of Pharmacognostic Evaluation

Pharmacognostic standardization forms the foundation for ensuring the identity, purity, quality, and consistency of herbal medicinal products. For *Passiflora caerulea* L., pharmacognostic evaluation is particularly important due to frequent adulteration and substitution with other *Passiflora* species, especially *P. incarnata* and *P. edulis*, which may differ significantly in phytochemical composition and pharmacological activity [14,15]. Comprehensive pharmacognostic assessment enables accurate botanical authentication and supports regulatory compliance for medicinal use. International guidelines, including those of the World Health Organization (WHO) and the Indian Pharmacopoeia Commission (IPC), emphasize the necessity of macroscopic, microscopic, physicochemical, and chromatographic parameters for herbal drug standardization [16,17].

7.2. Macroscopic (Organoleptic) Characteristics

Macroscopic evaluation provides a preliminary yet essential method for identifying *P. caerulea* raw materials. Key diagnostic features include:

- Leaves: Palmately 5-lobed, alternate, glossy green, with distinct petiolar glands
- Stem: Slender, green, striated, glabrous, bearing axillary tendrils
- Flowers: Large (8–10 cm), showy, white to pale pink perianth with blue-purple corona filaments
- Odor: Mild, characteristic
- Taste: Slightly bitter

These features assist in rapid field-level identification and help detect gross adulteration [13,14].

7.3. Microscopic Characteristics

Microscopic analysis is crucial for the authentication of powdered or processed plant materials. Diagnostic microscopic features of *P. caerulea* include:

- Epidermal cells: Polygonal with slightly sinuous anticlinal walls
- Stomata: Paracytic type, predominantly on the lower epidermis
- Trichomes: Sparse, unicellular covering trichomes
- Vascular tissue: Collateral vascular bundles with well-defined xylem and phloem
- Calcium oxalate crystals: Prismatic type, scattered within mesophyll tissues
- Secretory cells: Associated with flavonoid accumulation

These anatomical markers are consistent with pharmacognostic descriptions outlined in standard texts and monographs [13,14,18].

7.4. Physicochemical Parameters

Physicochemical evaluation ensures uniformity and quality of herbal raw materials. Parameters commonly assessed for *P. caerulea* include:

- Total ash value
- Acid-insoluble ash
- Water-soluble ash
- Loss on drying (moisture content)
- Alcohol-soluble extractive value
- Water-soluble extractive value

These parameters provide insight into inorganic contamination, adulteration, and extraction efficiency and must conform to limits specified by WHO and IPC guidelines [16,17].

7.5. Phytochemical Screening

Preliminary phytochemical screening of *P. caerulea* extracts consistently reveals the presence of:

- Flavonoids
- Alkaloids
- Phenolic compounds
- Glycosides
- Tannins

Qualitative tests such as Shinoda, Dragendorff's, Ferric chloride, and Bornträger's tests are commonly employed as initial screening tools before advanced chromatographic analysis [19].

7.6. Chromatographic Fingerprinting

Chromatographic profiling is essential for chemical standardization and batch-to-batch consistency.

7.6.1.Thin-Layer Chromatography (TLC / HPTLC)
TLC and HPTLC methods are widely used for detecting flavonoids such as vitexin and isovitexin. These techniques provide characteristic fingerprint profiles that serve as identity markers [5,15].

7.6.2.High-Performance Liquid Chromatography (HPLC)
HPLC methods enable precise quantification of marker compounds, particularly vitexin, isovitexin, and chrysin. These markers are critical for standardizing extracts intended for pharmacological or clinical use [5].

7.6.3.LC-MS/MS and Metabolomics
Advanced metabolomic approaches using LC-MS/MS allow comprehensive profiling of minor and major constituents, improving chemotaxonomic classification and quality assurance [9,30].

7.7. Detection of Adulterants and Contaminants
Quality-control evaluation also includes detection of:
- Heavy metals
- Pesticide residues
- Microbial contamination
- Aflatoxins

Ensuring compliance with permissible limits is essential for safety and regulatory approval of herbal products [16,17].

7.8. Significance of Quality-Control Parameters
The establishment of validated pharmacognostic and quality-control parameters ensures therapeutic consistency, patient safety, and regulatory acceptance of *P. caerulea*-based herbal products. Integrating classical pharmacognostic methods with modern chromatographic and metabolomic techniques provides a robust framework for standardization and commercial development [15,16,31].

VIII. RESEARCH GAPS AND FUTURE PERSPECTIVES

Despite the growing body of scientific literature supporting the ethnomedicinal relevance and pharmacological potential of *Passiflora caerulea* L., several critical research gaps remain that limit its translational application in evidence-based medicine. Addressing these gaps is essential for advancing *P. caerulea* from a traditionally used medicinal plant to a standardized, clinically validated phytotherapeutic agent.

8.1. Insufficient Clinical Evidence
The most prominent gap in *P. caerulea* research is the lack of well-designed clinical trials. Although preclinical studies have demonstrated anxiolytic, sedative, anti-inflammatory, antioxidant, and neuroprotective activities, the majority of these findings are derived from in vitro assays and animal models [11,12,21,23]. Human studies evaluating efficacy, safety, pharmacokinetics, and dose–response relationships are notably absent.
Future research must prioritize randomized, placebo-controlled clinical trials to validate traditional claims and preclinical findings. Such studies are essential for regulatory approval and integration of *P. caerulea* into modern therapeutic frameworks.

8.2. Limited Mechanistic Understanding
While several pharmacological activities of *P. caerulea* have been documented, mechanistic insights at the molecular and cellular levels remain incomplete. Existing studies largely focus on outcome-based observations rather than elucidating precise signaling pathways involved in its therapeutic effects [7,10,22]. Future investigations should employ molecular biology techniques to explore mechanisms such as receptor binding affinity, enzyme inhibition, gene expression modulation, and intracellular signaling pathways. Understanding the mechanistic basis of activity will enhance scientific credibility and support rational drug development.

8.3. Variability in Phytochemical Composition
Significant variation in phytochemical composition has been reported due to environmental factors, geographical location, cultivation practices, and extraction methods [9,34]. This variability complicates standardization and reproducibility of pharmacological outcomes.
Future research should focus on:
- Controlled cultivation strategies
- Chemotype identification
- Establishment of validated marker compounds
- Development of pharmacopeial monographs

Such efforts are crucial for ensuring consistent therapeutic efficacy and quality assurance [15–17].

8.4. Inadequate Toxicological Data

Although available studies suggest that *P. caerulea* is relatively safe at therapeutic doses, comprehensive toxicological evaluations are limited. Long-term toxicity, reproductive toxicity, genotoxicity, and herb–drug interaction studies are either scarce or entirely lacking [20,27,32].

Future studies should adopt internationally accepted toxicity-testing guidelines (OECD, WHO) to establish complete safety profiles. This is particularly important given the presence of cyanogenic glycosides and CNS-active alkaloids in the plant [18].

8.5. Lack of Standardized Extracts

Current pharmacological studies often employ non-standardized extracts, making cross-comparison difficult. Differences in solvent systems, extraction protocols, and dosage forms contribute to inconsistent results [15].

Future research should emphasize:

- Development of standardized extracts
- Quantification of bioactive markers (vitexin, isovitexin, chrysin)
- Stability studies
- Formulation development

These steps are essential for advancing *P. caerulea* toward pharmaceutical and nutraceutical commercialization [31,33].

8.6. Underexplored Therapeutic Applications

Most research on *P. caerulea* has focused on CNS-related activities, leaving other potential therapeutic applications underexplored. Preliminary evidence suggests possible benefits in inflammatory disorders, oxidative stress–related diseases, and neurodegenerative conditions [22,23,25].

Future studies should expand the therapeutic scope by exploring:

- Anti-inflammatory disease models
- Neurodegenerative disease models
- Metabolic and immunomodulatory effects

Such investigations could significantly broaden the medicinal relevance of *P. caerulea*.

8.7. Integration of Modern Technologies

Emerging technologies such as metabolomics, transcriptomics, network pharmacology, and artificial intelligence-based drug discovery remain largely unexplored in *P. caerulea* research [30,35]. Integration of these tools could accelerate identification of novel bioactive compounds and predict therapeutic targets more efficiently.

8.8. Future Perspectives

Considering its rich phytochemical diversity and promising pharmacological profile, *Passiflora caerulea* holds substantial potential for development as a safe and effective herbal therapeutic. Future research strategies should adopt a multidisciplinary approach combining ethnopharmacology, phytochemistry, pharmacology, toxicology, and clinical science.

The establishment of standardized extracts, comprehensive safety evaluation, and clinical validation will be key milestones in translating *P. caerulea* from traditional medicine to evidence-based healthcare applications.

IX. CONCLUSION

Passiflora caerulea L. is a medicinally important species of the Passifloraceae family with well-documented traditional use and growing scientific validation. Ethnomedicinal evidence, supported by modern phytochemical and pharmacological studies, demonstrates that the plant possesses significant anxiolytic, sedative, antioxidant, anti-inflammatory, neuroprotective, antimicrobial, and antispasmodic properties. These activities are primarily attributed to its rich content of flavonoids, particularly vitexin, isovitexin, and chrysin, along with supportive alkaloids and phenolic compounds.

Available preclinical studies indicate that *P. caerulea* exhibits a favorable safety profile at therapeutic doses; however, comprehensive clinical studies, long-term toxicity evaluations, and standardized extract development remain limited. Variability in phytochemical composition and lack of pharmacopeial monographs further emphasize the need for rigorous quality-control and standardization strategies.

In conclusion, *Passiflora caerulea* represents a promising yet underutilized medicinal plant with considerable potential for development as a validated

phytotherapeutic agent. Future research focusing on standardization, mechanistic studies, toxicological evaluation, and clinical validation is essential to support its integration into evidence-based herbal medicine.

ACKNOWLEDGEMENT

The authors are thankful to Management of Krishna School of Pharmacy & Research, Dr. Kiran and Pallavi Patel Global University (KPGU), Vadodara, Gujarat, India for providing all the supports to carry out the research work. We also acknowledge the stu dent start up innovation policy 2.0 (SSIP), Gujarat for providing the research grant.

REFERENCES

[1] Dhawan K., Kumar S., and Sharma A., "Anti-anxiety studies on extracts of *Passiflora incarnata* Linneaus," *J. Ethnopharmacol.*, vol. 78, no. 2–3, pp. 165–170, 2001.

[2] El-Askary H. I. *et al*., "Bioactivity-guided study of *Passiflora caerulea* L. leaf extracts," *J. Ethnopharmacol.*, vol. 310, p. 116455, 2024.

[3] Ozarowski M. *et al*., "Current progress on *Passiflora caerulea* L. in vitro culturing and metabolite production," *Molecules*, vol. 30, p. 1182, 2025.

[4] Smith A. B., "Comparative phytochemistry of the Passifloraceae family," *Phytochem. Rev.*, vol. 22, pp. 451–469, 2023.

[5] Garcia M. T. A., "Ethnobotanical uses of *Passiflora* species in South America," *Bot. J. Linn. Soc.*, vol. 198, pp. 323–338, 2022.

[6] Zhao L. *et al*., "Quantification of vitexin and isovitexin in medicinal plants using LC-MS," *J. Sep. Sci.*, vol. 47, no. 3, pp. 102–110, 2024.

[7] Patel R. K., "Flavonoid profiles of ornamental *Passiflora* species," *Plant Biosyst.*, vol. 157, no. 1, pp. 88–98, 2023.

[8] Brown E., "Role of chrysin in GABA modulation: A review," *Neurosci. Lett.*, vol. 801, pp. 136–145, 2025.

[9] Müller S. D., "Harmala alkaloids in *Passiflora*: Toxicological insights," *Arch. Toxicol.*, vol. 98, pp. 2135–2147, 2024.

[10] Khan J., "MAO-inhibitory effects of plant-derived indole alkaloids," *Drug Discov. Today*, vol. 28, p. 103427, 2023.

[11] Feuillet C., "Cyanogenic glycosides in *Passiflora* species," *Ann. Bot.*, vol. 121, pp. 1162–1169, 2018.

[12] Koo K. A. *et al*., "Overview of antioxidant and anti-inflammatory phytochemicals," *Phytomedicine*, vol. 86, p. 153556, 2021.

[13] Silva M. *et al*., "Sub-chronic toxicity of *Passiflora* flavonoid extracts," *Phytomedicine*, vol. 114, p. 154162, 2023.

[14] Costa C. M. *et al*., "Preliminary phytochemical screening of *Passiflora* species," *Phytomedicine*, vol. 104, p. 154306, 2022.

[15] Singh R. *et al*., "Standardization challenges of herbal extracts: *Passiflora* case study," *Phytochem. Anal.*, vol. 34, no. 4, pp. 512–520, 2023.

[16] World Health Organization, *Quality Control Methods for Medicinal Plant Materials*. Geneva, Switzerland: WHO Press, 2020.

[17] Indian Pharmacopoeia Commission, *Herbal Drug Standards*. Ghaziabad, India: IPC, 2022.

[18] W. C. Evans, *Trease and Evans Pharmacognosy*, 17th ed. Amsterdam, Netherlands: Elsevier, 2019.

[19] Khandelwal K. R., *Practical Pharmacognosy*, 25th ed. Pune, India: Nirali Prakashan, 2018.

[20] Herrera S., "Reproductive safety evaluation of *Passiflora* preparations," *Reprod. Toxicol.*, vol. 110, pp. 123–131, 2022.

[21] López V. *et al*., "Anxiolytic and sedative effects of *Passiflora* species," *J. Pharm. Pharmacol.*, vol. 73, pp. 180–192, 2021.

[22] Karimi A. *et al*., "Anti-inflammatory effects of plant flavonoids," *Front. Pharmacol.*, vol. 12, p. 676500, 2021.

[23] Martins N. *et al*., "Antioxidant properties of plant phenolics: A comprehensive review," *Food Chem.*, vol. 369, p. 130147, 2022.

[24] Borges E. M., "Neuroprotective potential of *Passiflora* flavonoids," *CNS Neurol. Disord. Drug Targets*, vol. 22, pp. 75–84, 2023.

[25] Sharma V. *et al*., "Antimicrobial activity of *Passiflora* extracts," *Ind. Crops Prod.*, vol. 176, p. 114291, 2022.

[26] Rohloff J. *et al*., "LC-MS metabolomic profiling of *Passiflora* species," *Plant Sci.*, vol. 327, p. 111540, 2023.

[27] Patel A. *et al*., "Pharmacological insights into *Passiflora* species," *Biomed Pharmacother.*, vol. 170, p. 113386, 2024.
[28] Banerjee P. *et al*., "Oxidative stress markers and herbal interventions," *J. Basic Clin. Physiol. Pharmacol.*, vol. 34, pp. 441–458, 2023.
[29] Orellana-Paucar A. M., "Antidepressant-like effects of *Passiflora* compounds," *Planta Med.*, vol. 87, pp. 498–506, 2021.
[30] Castillo A. *et al*., "Toxicity evaluation of *Passiflora* aqueous extracts," *Phytother. Res.*, vol. 35, pp. 2134–2140, 2021.
[31] Fernández M. *et al*., "Phytochemical variations in *Passiflora caerulea* under environmental stress," *Plant Physiol. Biochem.*, vol. 191, pp. 91–101, 2022.
[32] Almeida G. *et al*., "Anti-inflammatory mechanisms of plant extracts," *J. Ethnopharmacol.*, vol. 289, p. 115021, 2022.
[33] Rodrigues E. *et al*., "Medicinal use of *Passiflora* species: A systematic review," *Rev. Bras. Farmacogn.*, vol. 33, pp. 87–105, 2023.
[34] Zhao L. *et al*., "Metabolomics and chemotaxonomy of *Passiflora* species," *Plant Biosyst.*, vol. 158, pp. 77–89, 2024.
[35] Singh P. *et al*., "Future potential of *Passiflora*-based nutraceuticals," *Trends Food Sci. Technol.*, vol. 137, p. 105341, 2024.